ArticleFuture medicinal chemistry2012
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Article in Future medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Insights into the leveraging of GABAergic signaling in cancer therapy.Cancer medicine · 2023Review
- Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells.EXCLI journal · 2021Article
- Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.International journal of molecular sciences · 2019Review
- TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.The Journal of clinical investigation · 2018Article
- Recent Advances in Prostate Cancer Treatment and Drug Discovery.International journal of molecular sciences · 2018Review
- SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.EMBO molecular medicine · 2018Article
- Article
- Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.Medicine · 2017Article
- Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Oncotarget · 2017Article
- Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.Oncotarget · 2016Article
- Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.Oncotarget · 2015Article
- SRChing for the substrates of Src.Oncogene · 2014Review
- Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.The Prostate · 2014Article
- A transgenic mouse model for early prostate metastasis to lymph nodes.Cancer research · 2014Article
- Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.International journal of biological sciences · 2014Review
- Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.PloS one · 2014Article
- Dissecting the role of bone marrow stromal cells on bone metastases.BioMed research international · 2014Review
- Src controls castration recurrence of CWR22 prostate cancer xenografts.Cancer medicine · 2013Article
- Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.Cancer discovery · 2013Review
- Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.Oncology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The microenvironment is critical to the growth of prostate cancer (PCa) in the bone. Thus, for clinical efficacy, therapies must target tumor-microenvironment interactions. Several protein tyrosine kinases have been implicated in the development and growth of PCa bone metastasis. In this review, specific protein tyrosine kinases that regulate these complex interactions, including PDGFR, the EGFR family, c-Src, VEGFR, IGF-1R, FGFR and c-Met will be discussed, with an emphasis on why these kinases are promising therapeutic targets for metastatic PCa treatment. For each of these kinases, small-molecule inhibitors have reached clinical trials. Current results of these trials and future prospects for the use of tyrosine kinase inhibitors for the treatment of PCa bone metastases are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.